USPSTF Releases Draft PSA Screening Recommendation Update

The change was initiated by additional data demonstrating a decreased mortality risk associated with PSA screening.
The change was initiated by additional data demonstrating a decreased mortality risk associated with PSA screening.

The United States Preventative Service Task Force (USPSTF) released their draft update to their 2012 prostate-specific antigen (PSA) screening recommendation.1

The draft proposes the recommendation that clinicians educate men ages 55 to 69 about the potential benefits and harms of PSA screening for prostate cancer.

There are insufficient data to provide specific PSA screening recommendations for African American men, who are known to have a higher risk of prostate cancer and prostate cancer-specific mortality.

The update changes the 2012 Grade D recommendation — that the risks outweigh the benefits — to Grade C.

RELATED: PSA Nadir Identifies High-risk Cases of Localized Prostate Cancer

The change was initiated by additional data demonstrating a decreased mortality risk associated with PSA screening, though the risk-benefit ratio is closely balanced, according to the USPSTF statement.

The public is invited to comment on the draft recommendations until May 8, 2017.

Reference

  1. Draft recommendation statement: prostate cancer: screening. US Preventive Services Task Force website. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementDraft/prostate-cancer-screening1. Accessed April 19, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters